Santarus to Present at UBS Global Pharmaceuticals Conference

    Business Editors/Health/Medical Writers

    SAN DIEGO--(BUSINESS WIRE)--May 16, 2005--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that Gerald T. Proehl, president and chief executive officer, will make a presentation to the investment community at the UBS Global Pharmaceuticals Conference on Monday, May 23, 2005 at 3:30 pm Eastern Time, at the Grand Hyatt Hotel in New York City.
    Interested investors may gain access to a live audio webcast of the presentation via the Internet by visiting the Investor Relations section of the company's Web site at www.santarus.com. The presentation will be archived on the Web site and available for 14 days.

    About Santarus

    Santarus, Inc. is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products to enhance the quality of life for patients with gastrointestinal diseases and disorders. The company's current products are immediate-release formulations of omeprazole, a widely prescribed PPI. The company launched its first product, ZEGERID(R) Powder for Oral Suspension 20 mg, in October 2004 and launched ZEGERID Powder for Oral Suspension 40 mg in February 2005. The company submitted a new drug application for ZEGERID Capsules to the FDA in April 2005 and is also developing a chewable tablet formulation of ZEGERID. More information about Santarus is available on the company's Web site at www.santarus.com.

    Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus' business, including, without limitation, difficulties or delays in development, testing, manufacturing and marketing of and obtaining regulatory approval for Santarus' products, and other risks detailed in Santarus' prior press releases as well as in public periodic filings with the Securities and Exchange Commission.
    You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    Santarus(R) and ZEGERID(R) are trademarks of Santarus, Inc.

--30--SM/la*

CONTACT: Santarus, Inc. Martha L. Hough, 858-314-5824 Debra P. Crawford, 858-314-5708 or Investor Contact: Lippert/Heilshorn & Associates, Inc. Jody Cain (jcain@lhai.com) Bruce Voss (bvoss@lhai.com) 310-691-7100

KEYWORD: CALIFORNIA NEW YORK INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL TRADESHOW CONFERENCE CALLS SOURCE: Santarus, Inc.

Copyright Business Wire 2005